Loading financial data...

Matinas BioPharma Holdings, Inc. (MTNB) Financial Statements | Global Financial Data

Matinas BioPharma Holdings, Inc.

MTNBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1582554

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$1.1M	$3.2M	$33.0K	$158.3K	$89.8K
Research and Development Expense	$14.5M	$16.7M	$14.6M	$14.4M	$11.2M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$23.8M	-$24.6M	-$24.7M	-$24.2M	-$18.9M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$22.9M	—	—	—	—
Income Tax Expense (Benefit)	-$80.0K	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$25.1M	$44.8M	$61.3M	$71.0M	$40.2M
Assets, Current	$15.5M	$34.5M	$51.0M	$61.6M	$29.9M
Cash and Cash Equivalents, at Carrying Value	$6.8M	$21.0M	$12.4M	$22.2M	$22.2M
Liabilities	$5.9M	$8.2M	$8.8M	$7.2M	$7.2M
Liabilities, Current	$2.6M	$4.3M	$4.3M	$3.6M	$3.1M
Accounts Payable, Current	$514.0K	$618.0K	$937.0K	$349.9K	$679.3K
Stockholders' Equity Attributable to Parent	$36.6M	$52.5M	$63.7M	$33.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$15.3M	-$19.2M	-$15.2M	-$17.4M	-$14.1M
Net Cash Provided by (Used in) Investing Activities	$13.2M	$4.9M	$16.8M	-$40.7M	-$6.0M
Net Cash Provided by (Used in) Financing Activities	-$7.0K	$79.0K	$7.0M	$48.0M	$29.9M
Payments to Acquire Property, Plant, and Equipment	$218.0K	$892.0K	$260.0K	$5.7K	$405.6K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)